AstraZeneca's Antiplatelet Agent Brilinta Superior To Plavix In Phase III Trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Importantly for AstraZeneca's antithrombotic portfolio, the company's single Phase III trial for the investigational antiplatelet therapy Brilinta (ticagrelor) was a success - showing superior efficacy over Sanofi Aventis/Bristol-Myers Squibb's Plavix (clopidogrel) in a head-to-head comparison
You may also be interested in...
Can The Medicines Company Rebound From A Phase III Blow?
The Medicines Company will focus development of its reversible antithrombotic cangrelor on use as a "bridging" drug for patients who must break from Sanofi Aventis/Bristol-Myers Squibb's Plavix (clopidogrel) while undergoing surgery, after halting two Phase III trials in angioplasty patients because it was not showing approvable efficacy
Can The Medicines Company Rebound From A Phase III Blow?
The Medicines Company will focus development of its reversible antithrombotic cangrelor on use as a "bridging" drug for patients who must break from Sanofi Aventis/Bristol-Myers Squibb's Plavix (clopidogrel) while undergoing surgery, after halting two Phase III trials in angioplasty patients because it was not showing approvable efficacy
The Return Of The Blockbuster? Stage Is Set For Prasugrel Approval
FDA's handling of the advisory committee meeting for Lilly/Daiichi Sankyo's platelet inhibitor prasugrel is the first signal in some time that the agency is ready to approve a primary care drug to be used in large patient populations with relatively limited restrictions